Increased Risk of Death, Stroke and Heart Failure in Patients with Decompensated Heart Failure or Permanent Atrial Fibrillation

• In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; dronedarone doubles the risk of death. 
• Dronedarone is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.
• In patients with permanent atrial fibrillation, dronedarone doubles the risk of death, stroke and hospitalization for heart failure.
• Dronedarone is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm.